Premium
Risk Assessment for Aflatoxin: An Evaluation Based on the Multistage Model
Author(s) -
Bowers J.,
Brown B.,
Springer J.,
Tollefson L.,
Lorentzen R.,
Henry S.
Publication year - 1993
Publication title -
risk analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.972
H-Index - 130
eISSN - 1539-6924
pISSN - 0272-4332
DOI - 10.1111/j.1539-6924.1993.tb01325.x
Subject(s) - aflatoxin , risk assessment , computer science , environmental science , engineering , reliability engineering , risk analysis (engineering) , medicine , microbiology and biotechnology , biology , computer security
Lifetime cancer potency of alfatoxin was assessed based on the Yeh et al. study from China in which both aflatoxin exposure and hepatitis B prevalence were measured. This study provides the best available information for estimating the carcinogenic risk posed by aflatoxin to the U.S. population. Cancer potency of aflatoxin was estimated using a biologically motivated risk assessment model. The best estimate of aflatoxin potency was 9 (mg/kg/day) −1 for individuals negative for hepatitis B and 230 (mg/kg/day) −1 for individuals positive for hepatitis B.